Sign in
Intravitreal Aflibercept for Moderately Severe to Severe Non-Proliferative Diabetic Retinopathy (NPDR): The Phase 3 PANORAMA Study
Charles C Wykoff, MD, PhD, FASRS
Annual Meeting Talks
2018
ROP Screening With Ultra-widefield Imaging
Guillermo Salcedo-Villanueva, MD
Learnings From the Lampalizumab Chroma and Spectri Phase 3 Trials: Effect of Baseline Characteristics on Geographic Atrophy Progression
Carl D. Regillo, MD
Category: Pharmacology